Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception.

BACKGROUND The objective of this systematic review was to assess the safety and efficacy of subcutaneous recombinant (r) HCG and high-dose rLH compared with intramuscular urinary (u) uHCG for inducing final oocyte maturation and triggering ovulation. METHODS We searched the Cochrane Menstrual Disorders and Subfertility Group trials register (August 27, 2003), the Cochrane Central Register of Controlled Trials (CENTRAL on The Cochrane Library, issue 4, 2003), MEDLINE (1966 to February 2004) and EMBASE (1980 to February 2004). Searches were not limited by language. The bibliographies of included and excluded trials and abstracts of major meetings were searched for additional trials. Authors and pharmaceutical companies were contacted for missing and unpublished data. Only truly randomized controlled trials (RCTs) were included. Assessment of inclusion/exclusion, quality assessment and data extraction were performed independently by at least two reviewers. RESULTS Seven RCTs were identified, four comparing rHCG and uHCG and three comparing rhLH and uHCG. There was no statistically significant difference between rHCG and uHCG regarding the ongoing pregnancy/live birth rate [odds ratio (OR) 0.98; 95% confidence interval (CI) 0.69-1.39], clinical pregnancy rate, miscarriage rate or incidence of ovarian hyperstimulation syndrome (OHSS). There was no statistically significant difference between rhLH and uHCG regarding the ongoing pregnancy/live birth rate (OR 0.94; 95% CI 0.50-1.76), pregnancy rate, miscarriage rate or incidence of OHSS. rHCG was associated with a reduction in the incidence of local site reactions (OR 0.47; 95% CI 0.32-0.70). CONCLUSIONS According to these data, there is no evidence of a difference in clinical outcomes between urinary and recombinant gonadotrophins used for induction of final follicular maturation. Additional factors should be considered when choosing gonadotrophin type, including safety, cost and drug availability.

[1]  O. Hovatta,et al.  Recombinant LH is equally effective as recombinant hCG in promoting oocyte maturation in a clinical in-vitro maturation programme: a randomized study. , 2003, Human reproduction.

[2]  E. Littman,et al.  The combination of urinary and recombinant HCG improves outcome in patients with decreased oocyte/follicle ratio in previous cycles. , 2003, European journal of obstetrics, gynecology, and reproductive biology.

[3]  K. Doody,et al.  Use of recombinant human chorionic gonadotropin in ovulation induction. , 2003, Fertility and sterility.

[4]  W. Jiménez,et al.  Hemodynamic changes induced by urinary human chorionic gonadotropin and recombinant luteinizing hormone used for inducing final follicular maturation and luteinization. , 2002, Fertility and sterility.

[5]  L. O’Dea,et al.  Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer. , 2001, Fertility and sterility.

[6]  D. C. Knight,et al.  A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. , 2000, Human reproduction.

[7]  J. Balasch,et al.  Recurrent empty follicle syndrome successfully treated with recombinant human chorionic gonadotrophin. , 1999, Human reproduction.

[8]  G. Serour,et al.  Moderate ovarian hyperstimulation syndrome complicated by deep cerebrovascular thrombosis. , 1998, Human reproduction.

[9]  I. Trinchard-Lugan,et al.  Initiation of periovulatory events in gonadotrophin-stimulated macaques with varying doses of recombinant human chorionic gonadotrophin. , 1997, Human reproduction.

[10]  J. Antoine,et al.  [Clinical use of recombinant gonadotropins (FSH, LH, hCG)]. , 1997, Contraception, fertilite, sexualite.

[11]  E. Altieri,et al.  The empty follicle syndrome: a pharmaceutical industry syndrome. , 1995, Human reproduction.

[12]  Emperaire Jc.  [Therapeutic induction of ovulation: towards the replacement of hCG with LH]. , 1994 .

[13]  J. Emperaire,et al.  Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. , 1991, Human reproduction.

[14]  G. Serour,et al.  Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome. , 1990, Fertility and sterility.

[15]  Juan Balasch,et al.  Pregnancy after administration of high dose recombinant human LH alone to support final stages of follicular maturation in a woman with long-standing hypogonadotrophic hypogonadism. , 2003, Reproductive biomedicine online.

[16]  Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG. , 2001, Fertility and sterility.

[17]  Recombinant Human Luteinizing Hormone Is as Effective as, But Safer Than, Urinary Human Chorionic Gonadotropin in Inducing Final Follicular Maturation and Ovulation in in Vitro Fertilization Procedures: Results of a Multicenter Double-Blind Study* , 2001 .

[18]  Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment--recombinant HCG versus urinary HCG. The European Recombinant Human Chorionic Gonadotrophin Study Group. , 2000, Human reproduction.

[19]  J. Emperaire.  [Therapeutic induction of ovulation: towards the replacement of hCG with LH]. , 1994, Contraception, fertilite, sexualite.

[20]  J. Pierce,et al.  Glycoprotein hormones: structure and function. , 1981, Annual review of biochemistry.